We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen offers comprehensive, multi-method protein aggregation analysis for characterizing aggregate formation, size distribution, and stability—supporting risk assessment and mitigation throughout biotherapeutic development, formulation, and manufacturing.
Proteins are prone to aggregation under environmental stress (e.g., pH or temperature shifts), which can compromise safety and efficacy, potentially triggering adverse immune responses. Despite their critical role as stability indicators, protein aggregates remain challenging to measure and often require advanced instrumentation.
As a leader in bioanalysis, Profacgen has established a robust aggregation analysis platform integrating reliable conventional methods with novel high-resolution, high-efficiency strategies for superior characterization.
Why Protein Aggregation Matters
Figure 1. Summary of the consequences of protein aggregation. (Rojekar et al., 2025)
Protein aggregation is a critical quality attribute that impacts efficacy, safety, and manufacturability throughout the biopharmaceutical lifecycle:
Reduced efficacy: Aggregate formation sequesters active monomer, decreases bioavailability, and alters target binding kinetics, compromising therapeutic potency
Altered pharmacokinetics: Aggregates exhibit modified clearance rates, distribution profiles, and tissue penetration compared to monomeric species, leading to unpredictable exposure and dosing
Increased immunogenicity: Protein aggregates can trigger anti-drug antibody responses, neutralizing activity, hypersensitivity reactions, and loss of therapeutic benefit
Manufacturing challenges: Aggregation during expression, purification, and fill-finish operations reduces yield, complicates process control, and increases cost of goods
Reliable aggregation analysis is essential for developability assessment, formulation optimization, process validation, and regulatory compliance.
What Can Protein Aggregation Analysis Reveal?
Profacgen's multi-method platform delivers comprehensive quantitative information across the critical aggregation attributes of biotherapeutic samples:
Aggregate Formation: Detection and quantification of oligomeric species, subvisible particles, and visible precipitates arising from thermal, chemical, mechanical, or storage stress
Aggregate Size Distribution: Population analysis spanning soluble oligomers (nm scale) through submicron and micron-scale particulates, revealing monodisperse, bimodal, or polydisperse distributions
Soluble Aggregates: Characterization of reversible and irreversible oligomeric species in the subvisible range, including dimers, trimers, and higher-order oligomers
Insoluble Aggregates: Detection and morphology analysis of precipitated, fibrillar, or amorphous particulates that compromise injectability and safety
Aggregation Kinetics: Time-dependent monitoring of aggregate growth rates, nucleation phases, and propagation kinetics under isothermal or accelerated stress conditions
Stress-Induced Aggregation: Assessment of thermal, agitation, freeze-thaw, pH, and ionic strength effects on aggregation propensity to identify robust formulations and storage conditions
Colloidal Stability: Evaluation of protein-protein interaction parameters, repulsive forces, and solution conditions promoting or preventing self-association
Our Protein Aggregation Analysis Capabilities
Profacgen provides a combined toolbox of well-established and advanced analytical methods, each selected for optimal resolution, sensitivity, and reliability for your specific aggregation question.
Sensitive detection of early aggregate formation and hydrodynamic size assessment.
Early aggregation detection: Identification of oligomeric species and subtle shifts in hydrodynamic radius before visible precipitation occurs
Particle size assessment: Intensity-weighted and volume-weighted size distributions revealing monomer, oligomer, and large aggregate populations
SEC-Based Aggregation Analysis
High-resolution separation and quantification of monomeric and aggregated species.
Monomer/aggregate quantification: Percent monomer, high-molecular-weight species (HMWS), and low-molecular-weight species (LMWS) by peak area integration
Purity assessment: Detection of clipped variants, fragments, and process-related impurities alongside aggregate populations
Light Scattering Analysis
Multi-angle and static light scattering for molecular weight and assembly characterization.
Aggregate characterization: Absolute molecular weight determination of monomeric and oligomeric species independent of calibration standards
Molecular assembly evaluation: Stoichiometry inference, association constant estimation, and complex formation analysis
Thermal Stress Studies
Temperature-dependent aggregation profiling for stability ranking and formulation screening.
Temperature-induced aggregation: Real-time monitoring of thermal denaturation, aggregation onset temperature (Tagg), and growth kinetics
Stability ranking: Comparative assessment of candidates, formulations, or process conditions based on thermal aggregation resistance
Formulation Screening
Rapid, systematic evaluation of buffer and excipient effects on aggregation propensity.
Buffer optimization: pH, ionic strength, and buffer species screening to minimize electrostatic and hydrophobic interactions promoting aggregation
Excipient selection: Surfactant, osmolyte, and stabilizer evaluation for colloidal and conformational stability enhancement
Developability assessment: Early-stage aggregation risk profiling to identify robust, manufacturable candidates before resource-intensive investment
Sample Types
Our aggregation analysis platform accommodates diverse biotherapeutic and research sample classes:
Monoclonal Antibodies: IgG1, IgG2, IgG4 subclasses; wild-type and Fc-engineered variants; biosimilar and innovator products
Bispecific Antibodies: Asymmetric and symmetric formats; chain-pairing variants; multi-valent architectures
Fc Fusion Proteins: Cytokine fusions, receptor fusions, and peptide fusions with Fc-mediated self-association risks
Recombinant Proteins: Enzymes, growth factors, hormones, and cytokines with diverse folding and stability profiles
Vaccines: Antigen-adjuvant complexes, virus-like particles, and subunit vaccines with particle assembly and disassembly concerns
Protein Complexes: Multi-subunit assemblies, protein-protein interaction networks, and transient complexes with concentration-dependent association
Aggregation Risk Assessment Workflow
Our engagement workflow is designed to systematically identify, characterize, and mitigate aggregation risks:
Sample Evaluation: Initial assessment of sample history, formulation, concentration, and intended use to define appropriate analytical strategy and acceptance criteria
Aggregation Detection: Multi-method screening (DLS, SEC, light scattering) to identify aggregate species, quantify monomer loss, and characterize size distribution
Stress Testing: Accelerated thermal, agitation, freeze-thaw, and pH stress to reveal latent aggregation propensity and rank formulation or candidate stability
Data Interpretation: Integration of orthogonal analytical results, correlation with structural and biophysical data, and mechanistic inference of aggregation pathways (nucleation, growth, surface adsorption)
Optimization Recommendations: Formulation, process, or molecular engineering recommendations to minimize aggregation risk, supported by follow-up validation studies
Deliverables
Profacgen provides structured, decision-ready documentation aligned with your analytical and regulatory requirements:
Aggregate Profile: Quantitative monomer, oligomer, and high-molecular-weight species distribution by SEC with peak area percentages and method details
Particle Size Distribution: Intensity-weighted and volume-weighted hydrodynamic size distributions by DLS with polydispersity index and population deconvolution
Aggregation Trend Analysis: Time-dependent and stress-dependent aggregate growth kinetics, nucleation rates, and stability half-lives with statistical modeling
Stability Assessment: Comparative ranking of candidates, formulations, or process conditions based on aggregation resistance under thermal, mechanical, and storage stress
Technical Report: Comprehensive documentation of methods, raw data, analyzed results, statistical evaluation, and expert interpretation suitable for regulatory submission, internal review, or publication support
Why Choose Our Protein Aggregation Analysis Services?
Multi-Method Characterization Strategy: We integrate SEC, DLS, light scattering, and thermal stress analysis to provide convergent, high-confidence aggregate characterization—no single method can capture the full aggregation landscape.
Sensitive Aggregate Detection: Our advanced instrumentation detects soluble oligomers, subvisible particles, and early-stage aggregates before they impact product quality or safety, enabling proactive risk mitigation.
Customized Study Design: We tailor analytical strategies to your specific molecule, development stage, and decision point—whether for early screening, formulation optimization, or regulatory comparability.
Biologics Development Expertise: Our scientists combine deep protein biochemistry knowledge with extensive pharmaceutical development experience, ensuring that aggregation data are translated into actionable formulation, process, and molecular design recommendations.
A therapeutic antibody development program required a stable, manufacturable high-concentration (150 mg/mL) formulation for subcutaneous delivery. Initial formulations exhibited unacceptable levels of subvisible particles and viscosity increases during accelerated stability testing, threatening program timelines and patient safety.
Objective:
To identify formulation conditions that minimize aggregation, reduce viscosity, and maintain monomer content >98% under accelerated thermal and mechanical stress, using a systematic, multi-method analytical approach.
Approach:
Profacgen designed a 36-condition formulation matrix evaluating pH (5.0–7.0), buffer species (histidine, acetate, citrate), ionic strength, and excipients (arginine, proline, sucrose, polysorbate). Each condition was assessed by SEC for monomer/HMWS content, DLS for hydrodynamic size and polydispersity, and micro-flow imaging for subvisible particle counts. Thermal stress studies (40°C, 4 weeks) and agitation stress (400 rpm, 7 days) were applied to reveal latent instability. Colloidal stability parameters (B22, kD) were measured by static and dynamic light scattering to guide formulation selection.
Outcome:
A histidine-arginine-sucrose formulation at pH 6.0 was identified that maintained >99% monomer by SEC, PDI <0.05 by DLS, and subvisible particle counts below regulatory thresholds after all stress conditions. Viscosity at 150 mg/mL was reduced by 40% compared to initial formulations. The optimized formulation progressed to long-term stability studies and clinical manufacturing with confidence.
A biosimilar development program required rigorous demonstration of aggregate profile equivalence between a candidate monoclonal antibody and the reference innovator product. Aggregate content—particularly high-molecular-weight species and subvisible particles—was a critical quality attribute for regulatory approval.
Objective:
To execute a comprehensive, multi-method comparability study demonstrating equivalent monomer content, HMWS levels, size distribution, and subvisible particle burden between the biosimilar candidate and reference product, supported by statistical analysis and system suitability documentation.
Approach:
Profacgen conducted side-by-side analysis using SEC-HPLC with multi-angle light scattering (MALS) for absolute molecular weight confirmation, DLS for hydrodynamic size distribution, and micro-flow imaging for subvisible particle enumeration. Multiple independent batches of candidate and reference products were analyzed under identical conditions. Statistical equivalence testing (TOST) was applied to monomer and HMWS percentages. Forced degradation studies (thermal, oxidative, agitation) were performed to compare stress-induced aggregation propensity and reveal potential differences in conformational stability.
Outcome:
The biosimilar candidate demonstrated monomer content within ±0.5% and HMWS within ±0.2% of the reference product across all batches and conditions. DLS size distributions were statistically indistinguishable (correlation coefficient >0.98), and subvisible particle counts were equivalent and below regulatory thresholds. Stress-induced aggregation kinetics were comparable, supporting equivalent conformational stability. The comprehensive dataset and structured report supported regulatory submission and accelerated clinical development.
Q: What is the difference between soluble and insoluble aggregates?
A: Soluble aggregates remain dispersed in solution and include oligomers (dimers, trimers, higher-order species) typically detected by SEC and DLS. Insoluble aggregates precipitate from solution and include visible particles and subvisible particulates detected by light obscuration, micro-flow imaging, or centrifugation. Both types impact efficacy and safety, but require different analytical methods for detection and quantification.
Q: Why is SEC not sufficient for complete aggregation analysis?
A: SEC is excellent for separating and quantifying soluble aggregates by size, but has limitations: column interactions can cause artificial aggregate loss or formation, very large aggregates may be excluded or filtered, and insoluble particles are not detected. DLS provides complementary size distribution information without column separation. Light scattering and imaging methods detect insoluble species. A multi-method approach is essential for comprehensive aggregate characterization.
Q: What causes protein aggregation during manufacturing?
A: Common causes include: high protein concentration during formulation and fill-finish; mechanical stress from pumping, filtration, and filling; temperature excursions during storage and transport; pH shifts during buffer exchange; freeze-thaw cycles; and surface adsorption to containers and interfaces. Profacgen's aggregation analysis can identify process steps promoting aggregation and guide optimization.
Q: How does aggregation affect immunogenicity?
A: Protein aggregates can trigger immune responses through multiple mechanisms: enhanced uptake by antigen-presenting cells, epitope presentation on MHC molecules, activation of B cells through multivalent antigen display, and molecular mimicry of pathogen-associated patterns. Aggregates may also expose cryptic epitopes hidden in the native monomer. Regulatory agencies require rigorous aggregate control and monitoring for this reason.
Q: What is the best method for early-stage aggregation detection?
A: DLS is highly sensitive for early aggregation detection due to its sixth-power dependence on particle size—small amounts of large aggregates produce strong signals. It requires minimal sample, operates without column separation, and provides rapid results. However, DLS is less quantitative for mixed populations than SEC. We recommend DLS for screening and early detection, combined with SEC for quantitative monomer/aggregate distribution.
References:
Rojekar S, Gholap AD, Jadhav K, et al. Exploring protein aggregation in biological products: from mechanistic understanding to practical solutions. AAPS PharmSciTech. 2025;26(6):189. doi:10.1208/s12249-025-03189-2
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. Summary of the consequences of protein aggregation. (Rojekar et al., 2025)